Cell-Type Specific Nuclei Profiling for Human Drug Target Discovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for identifying drug targets in specific cell types, such as TRAP, rely on transgenic mice, which may not accurately represent human gene expression and are limited by species differences and individual variability, lacking the ability to directly profile human tissues and account for inter-individual gene expression variations.
Innovation Solution
A method involving tissue sample processing to expose nuclei, labeling with affinity labels specific to cell-type unique nucleic acid transcripts or proteins, followed by purification and data collection to profile gene and epigenetic expression, enabling cell-type specific profiling in human tissues without transgenic animals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If transgenic mice are used for target identification (TRAP method), then cell type specific gene expression can be profiled, but species differences limit accuracy for human drug targets
Solution Approach 1:
The patent creates transgenic mice that carry human cDNAs under the control of cell-type specific regulatory elements. This allows copying human gene expression patterns in a mouse model system, enabling accurate profiling of human cell-type specific gene expression while utilizing the technical advantages of mouse models for drug target identification
Solution Approach 2:
The patent uses transgenic mice as an intermediary system between human tissue and drug target identification. By introducing human cDNAs into mice with cell-type specific promoters, the system mediates the translation of human gene expression patterns into a tractable model for high-throughput screening and target validation
2Productivity
If bulk tissue analysis is performed, then sample requirements are minimal, but cell type specific signal is diluted by other cell types
Solution Approach 1:
The patent segments the heterogeneous bulk tissue signal into distinct cell-type specific components by using transgenic mice expressing reporter genes under cell-type specific promoters. This allows isolation and analysis of gene expression signals from specific cell types (e.g., neurons, glia) within the complex tissue environment, preventing signal dilution while maintaining screening capability
Solution Approach 2:
The patent applies local quality by creating transgenic lines where specific genes are expressed only in particular cell types or regions. This spatial and cellular specificity allows the study of local gene expression patterns without contamination from other cell types, enhancing detection sensitivity for cell-type specific targets
3Measurement precision
If transgenic mouse lines are developed for each cell type, then cell type specificity is achieved, but time and resources required for line development increase
Solution Approach 1:
The patent develops a universal platform using cell-type specific promoters that can drive expression of multiple different cDNAs in the same transgenic line. This multi-functional approach allows a single promoter construct to be used across multiple gene studies, eliminating the need to develop separate transgenic lines for each gene-cell type combination and significantly reducing development time
Solution Approach 2:
The patent performs preliminary action by establishing a library of validated cell-type specific promoters and regulatory elements before conducting drug target screening. This pre-characterized toolkit allows rapid generation of transgenic lines for any gene of interest without repeated optimization, accelerating the overall target identification process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides reproducible, cell-type specific gene and epigenetic profiles in human tissues, allowing for the identification of drug targets and understanding variability across individuals, which can inform therapeutic development and patient stratification.
Implementation Method 1
labeling with affinity labels specific to cell-type unique nucleic acid transcripts or proteins
Implementation Method 2
labeling with affinity labels specific to cell-type unique nucleic acid transcripts or proteins
Implementation Method 3
The sorted nuclei can then be used for sequencing or other analyses
Data Source
AI summary
The present invention provides methods of profiling gene and protein expression of a plurality of nuclei from a single cell type and comparing the profiles to determine variability among cell populations, samples from different subjects, and cells expressing a disease phenotype.